Table 2.

The five items of the revised Bethesda guideline (RBG) and additional items

Relevant genes in respective itema
1	2	3	4	6	7	8	10	11c	12d
FAT4b	EPHA3 HELZ2 MEGF8 SI SPTA1 UNC79	BMPR2 DST ERBB4 FAT1 FAT4 KDM5A MUC16 UBR5	BMPR2 MSH3	SETD5	ANKS1A BMPR2 CNOT1 DNHD1 DST FAT1 FAT4 FREM2 HELZ2 HSPG2 INO80 KDM5A LRRC7 MEGF8 MGA MSH3 MUC12 MUC16 PCNT RAI1 REV3L RIMS2 SCAF4 SEC31A SLC8A1 SYNE1 TTN USP40 ZC3H13	DNAH3 HELZ2 MUC16 PCDH17 SCAF4 SLC8A1	ANKS1A BMPR2 CNOT1 DNHD1 DST FAT1 FREM2 HELZ2 HSPG2 INO80 KDM5A LRRC7 MEGF8 MSH3 MUC16 PCNT RAI1 REV3L RIMS2 SCAF4 SEC31A SLC8A1 SYNE1 USP40 VPS13C ZC3H13	ANKS1A C2orf16 CACNA1D CDH1 CDH10 CNOT DCLK1 DGKH HCFC1 PCDH19 PRDM2 PTPRQ RAI1 RBBP8 SI SYNE1 TOP2B TRIO USP40 VPS13C XPOT	HCFC1 HSPG2 USP40

Underscored genes indicated higher mutation rate with increased mRNA expression in the positive group compared with the negative group

^aAll items are precisely defined in the Table 1

^bExceptionally showing lower mutation rate in the positive group

^cPositive group = left colon cancer, negative group = right colon cancer

^dPositive group = rectal cancer, negative group = colon cancer